Compare Gitlab Inc (GTLB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs 10X Genomics Inc — how do they compare? Gitlab Inc trades at $41.21 (market cap $7.11B), while 10X Genomics Inc trades at $57.02 (market cap $7.61B). The key difference: Gitlab Inc and 10X Genomics Inc are close in size by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | TXG | |
|---|---|---|
Market Cap | $7.11B | $7.61B |
Sector | Technology | Health |
52-Week High | $51.04 | $58.57 |
52-Week Low | $19.42 | $11.34 |
Enterprise Value | $5.85B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $40.98, up 0.61% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Revenue grew to $759.25M in 2025, with a high gross margin of 86.74%, but net income remains negative. Recent news highlights AI-driven product launches and Gartner leadership recognition, fueling positive sentiment.
Outlook: Growth prospects are robust due to AI integration and market position, but high valuation (P/E 521.22) and lack of profitability pose risks. Analyst consensus is mixed with a $32.92 price target, suggesting caution despite operational strengths.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
